CLINICAL TRIALS PROFILE FOR NICOTINE

505(b)(2) Clinical Trials for NICOTINE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00224419 ↗	Testing Pharmacological Therapies for Pregnant Smokers	Terminated	National Cancer Institute (NCI)	Phase 4	2003-06-01	Nicotine dependence has not been sufficiently addressed in current state-of-the-science cessation interventions for pregnant smokers. The weight of the evidence from the general population of smokers suggests that nicotine replacement therapies may be beneficial cessation aids for pregnant smokers who are unable to stop smoking. The tremendous potential of these therapies for promoting smoking cessation among pregnant women creates a pressing need for decision tools and protocols to encourage treatment adherence that is essential for rigorous evaluation of the effectiveness of OTC NRT when provided as part of prenatal care. The results of this research could be directly translated to the improvement of obstetrical care providers' clinical practices. Medically supervised use of OTC NRT by pregnant smokers is an alternative to continued smoking that has the potential to substantially increase rates of smoking cessation during pregnancy.
OTC	NCT00224419 ↗	Testing Pharmacological Therapies for Pregnant Smokers	Terminated	Duke University	Phase 4	2003-06-01	Nicotine dependence has not been sufficiently addressed in current state-of-the-science cessation interventions for pregnant smokers. The weight of the evidence from the general population of smokers suggests that nicotine replacement therapies may be beneficial cessation aids for pregnant smokers who are unable to stop smoking. The tremendous potential of these therapies for promoting smoking cessation among pregnant women creates a pressing need for decision tools and protocols to encourage treatment adherence that is essential for rigorous evaluation of the effectiveness of OTC NRT when provided as part of prenatal care. The results of this research could be directly translated to the improvement of obstetrical care providers' clinical practices. Medically supervised use of OTC NRT by pregnant smokers is an alternative to continued smoking that has the potential to substantially increase rates of smoking cessation during pregnancy.
OTC	NCT00405912 ↗	St. John's Wort for Tobacco Cessation	Completed	National Cancer Institute (NCI)	Phase 2	2005-09-01	After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 23%. Currently available treatments among adults are expensive and not efficacious for all tobacco users. New pharmacologic agents need to be developed and tested to achieve the Healthy People 2010 goal of less than a 12% adult tobacco use prevalence. Bupropion, an FDA approved agent for tobacco cessation, acts by inhibiting central synaptosomal reuptake of dopamine and norepinephrine. A widely used herbal antidepressant, St. John's Wort (SJW), shares a similar mechanism of action and is effective for treating mild to moderate depression. SJW is well tolerated, available over the counter, and is significantly less expensive than the established treatments for tobacco dependence. To date, no prospective clinical trial evaluating the efficacy of SJW for the treatment of tobacco use has been published. We propose to evaluate the efficacy of SJW for increasing tobacco abstinence and decreasing nicotine withdrawal symptoms in a randomized, double-blind, placebo-controlled, three-arm, parallel group, dose-ranging clinical trial. Participants (N=120) will be randomly assigned to one of the three groups and will receive a twelve-week course of SJW 900 mg per day, 1800 mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism.
OTC	NCT00405912 ↗	St. John's Wort for Tobacco Cessation	Completed	Mayo Clinic	Phase 2	2005-09-01	After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 23%. Currently available treatments among adults are expensive and not efficacious for all tobacco users. New pharmacologic agents need to be developed and tested to achieve the Healthy People 2010 goal of less than a 12% adult tobacco use prevalence. Bupropion, an FDA approved agent for tobacco cessation, acts by inhibiting central synaptosomal reuptake of dopamine and norepinephrine. A widely used herbal antidepressant, St. John's Wort (SJW), shares a similar mechanism of action and is effective for treating mild to moderate depression. SJW is well tolerated, available over the counter, and is significantly less expensive than the established treatments for tobacco dependence. To date, no prospective clinical trial evaluating the efficacy of SJW for the treatment of tobacco use has been published. We propose to evaluate the efficacy of SJW for increasing tobacco abstinence and decreasing nicotine withdrawal symptoms in a randomized, double-blind, placebo-controlled, three-arm, parallel group, dose-ranging clinical trial. Participants (N=120) will be randomly assigned to one of the three groups and will receive a twelve-week course of SJW 900 mg per day, 1800 mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism.

All Clinical Trials for NICOTINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000284 ↗	Role of Metabolites in Nicotine Dependence (1) - 1	Completed	University of Minnesota	Phase 2	1995-02-01	The purpose of this study is to determine the effects of cotinine with or without a transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000284 ↗	Role of Metabolites in Nicotine Dependence (1) - 1	Completed	University of Minnesota - Clinical and Translational Science Institute	Phase 2	1995-02-01	The purpose of this study is to determine the effects of cotinine with or without a transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000284 ↗	Role of Metabolites in Nicotine Dependence (1) - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1995-02-01	The purpose of this study is to determine the effects of cotinine with or without a transdermal nicotine replacement on tobacco withdrawal symptoms.
NCT00000288 ↗	Role of Metabolites in Nicotine Dependence (2) - 5	Completed	University of Minnesota	Phase 2	1995-12-01	The purpose of this study is to determine the effects of varying doses of cotinine on cigarette self-administration.

Clinical Trial Conditions for NICOTINE

Condition Name

Condition Name for NICOTINE
Intervention	Trials
Smoking Cessation	215
Nicotine Dependence	147
Smoking	116
Tobacco Use Disorder	103

Condition MeSH

Condition MeSH for NICOTINE
Intervention	Trials
Tobacco Use Disorder	329
Schizophrenia	56
Alcoholism	41
Substance-Related Disorders	35

Clinical Trial Locations for NICOTINE

Trials by Country

Trials by Country for NICOTINE
Location	Trials
Canada	54
Sweden	29
France	26
Germany	18
China	15

Trials by US State

Trials by US State for NICOTINE
Location	Trials
California	95
Connecticut	74
Minnesota	66
Pennsylvania	65
North Carolina	63

Clinical Trial Progress for NICOTINE

Clinical Trial Phase

Clinical Trial Phase for NICOTINE
Clinical Trial Phase	Trials
PHASE4	20
PHASE3	3
PHASE2	8

Clinical Trial Status

Clinical Trial Status for NICOTINE
Clinical Trial Phase	Trials
Completed	626
Recruiting	119
Not yet recruiting	76

Clinical Trial Sponsors for NICOTINE

Sponsor Name

Sponsor Name for NICOTINE
Sponsor	Trials
National Institute on Drug Abuse (NIDA)	213
National Cancer Institute (NCI)	89
Yale University	61

Sponsor Type

Sponsor Type for NICOTINE
Sponsor	Trials
Other	1185
NIH	421
Industry	202

Nicotine (Smoking Cessation and Nicotine Replacement) Clinical Trials Update, Market Analysis, and Projections

Last updated: April 27, 2026

What nicotine products are clinically active and how are trials structured?

“Nicotine” is not a single prescription drug product. It is an active pharmaceutical ingredient delivered through multiple nicotine replacement therapy (NRT) formats and used across smoking cessation programs, often under national guidelines that include behavioral counseling. Clinical development and trials generally evaluate:

• Efficacy of delivery systems (dose, pharmacokinetics, patch vs gum vs lozenge vs inhaler vs oral spray)
• Safety and tolerability (adverse events, adherence, formulation tolerability)
• Real-world cessation outcomes (biochemically confirmed abstinence at follow-up)

Across major product classes, trial endpoints typically include:

• Continuous abstinence from a target date at 4 to 26 weeks
• Point-prevalence abstinence at 4 to 6 weeks, then later follow-up (often 6 to 12 months)
• Biochemical confirmation (commonly exhaled carbon monoxide or cotinine testing) in more rigorous studies

Regulatory positioning is consistent: nicotine replacement is used to reduce withdrawal symptoms and cravings while discontinuing smoking or using less nicotine.

What is the clinical trials update for nicotine in smoking cessation?

For NRT nicotine, the clinical trial “update” is less about new molecular entities and more about incremental evidence and comparative effectiveness across delivery routes. Recent public evidence and guideline updates emphasize that nicotine can be delivered in different forms and used alone or in combination (for example, patch for baseline exposure plus short-acting forms for breakthrough cravings), with effectiveness influenced by adherence and dosing adequacy.

Key clinical evidence pattern (across NRT formats)

Clinical evidence consolidations consistently find:

• NRT improves smoking abstinence vs placebo or usual care.
• Combining long-acting (patch) with short-acting (gum/lozenge/oral forms) improves outcomes in many settings.
• Dose adequacy matters for heavier smokers.

This evidence base supports ongoing pragmatic trials focused on:

• Adherence interventions
• Switches between formats
• Combination regimens
• Titration strategies
• Implementation in primary care and stop-smoking services

Real-world trial emphasis reflected in guidelines

Major clinical guidelines now frame nicotine NRT as part of structured cessation care with stepped support. Examples include U.S. and UK cessation guidance that endorse NRT dosing and combination use where clinically appropriate (evidence-based approach reflected in their recommendations) [1–4].

What is the current market landscape for nicotine NRT?

Market definition and how investors should segment it

For market analysis, the practical investable unit is nicotine NRT product supply by:

• Form factor (patch, gum/chew, lozenge, inhaler, oral spray, pouches in some regions)
• Channel (OTC vs pharmacy vs clinical program distribution)
• Geography (U.S., EU-5, UK, Canada, Australia, other)

Most revenue is concentrated in established brands and widely distributed OTC lines. Pricing and volumes are highly sensitive to reimbursement structures (where applicable) and to public health campaign cycles.

Supply and product set (high-level)

Nicotine NRT includes:

• Transdermal patches (long-acting)
• Oral forms (gum, lozenges, oral strips or sprays depending on market)
• Inhaler devices (less common in some jurisdictions) Each maintains the same active ingredient (nicotine) but differs materially in patient experience, bioavailability, and adherence drivers.

How large is the nicotine NRT market and what drives growth?

Market growth drivers

Across NRT, growth typically reflects:

• Continued prevalence of tobacco use and population turnover
• Public health initiatives and cessation program funding
• OTC accessibility and pharmacy shelf availability
• Improved adherence formats and combination regimens
• Increased clinician and payer adoption of structured cessation care

Market headwinds

• Generic competition in many formats
• Price pressure in OTC categories
• Substitution by alternative cessation pharmacotherapies (varenicline, cytisine where approved, bupropion)
• Regulatory shifts affecting packaging, labeling, and promotional constraints

Projection logic that holds for nicotine NRT

Because nicotine NRT is mature, growth tends to track: 1) total cessation attempts, 2) share of cessation attempts using NRT, 3) persistence/adherence improvements by format or delivery innovations.

What are projections for nicotine NRT revenue and demand?

Projection framework (drug-agnostic to molecule, market-appropriate)

For a mature active ingredient like nicotine, projections should be built on:

• Units: average treatment duration multiplied by number of quit attempts using NRT
• Mix: shift between patch-only vs combination regimens; move toward faster-relief formats as “craving management”
• Pricing: inflation and competitive dynamics; OTC promotional intensity; tendering dynamics where public programs exist

Market projection direction

• Base case: modest steady growth or stable-to-slightly up volumes due to ongoing tobacco burden and substitution dynamics.
• Upside: higher combination use plus better adherence and expansion of cessation services.
• Downside: aggressive generics pricing and substitution to other cessation drugs in markets with strong payer formularies.

Because nicotine NRT is widely available and often generically sold, projections should be treated as category-level and channel-level. Exact forecasts depend on geography and channel share.

How do patents and exclusivity affect nicotine commercial economics?

Nicotine as an ingredient is not meaningfully protected at the active level because long-standing NRT products are mostly old and have entered generic territory. Commercial leverage therefore comes from:

• Device and formulation IP (patch matrices, delivery systems, adhesives, flavoring/film coatings)
• Method-of-use or regimen IP (combination dosing protocols and titration strategies)
• Branding and service frameworks where permitted
• Regulatory exclusivity tied to specific formulations and manufacturing processes rather than nicotine itself

From a patent-investment perspective, the relevant question is not “Is nicotine protected?” but “Which delivery and formulation improvements still have enforceable IP in the target geography?”

What competitive landscape should be modeled?

Substitution set

Nicotine NRT competes with:

• Other pharmacotherapies: varenicline, bupropion
• Non-pharmacologic programs: counseling plus digital supports
• Cytisine in jurisdictions where approved (varies by country)
• E-cigarette and heated tobacco-derived nicotine products (regulatory and evidence framework vary)

Market share shifts are driven by:

• clinician preference and guidance updates,
• patient preference for speed of craving relief,
• adverse event profiles and contraindications,
• payer coverage for non-NRT drugs.

What compliance and safety signals matter for market access?

Nicotine NRT labeling and use is constrained by safety guidance on:

• overdose risk if users continue smoking while using NRT
• contraindications and precautions by age and comorbidities
• pregnancy and lactation counseling pathways in national guidance

Clinically, the main safety burden is predictable nicotine-related effects (nausea, dizziness, irritation at patch site, mouth/throat irritation for oral/spray formats), typically mitigated by dose titration and correct use.

What is the actionable strategic outlook for R&D and investment?

If you are funding incremental product development

Highest ROI areas typically include:

• Improving adherence via user-friendly dosing and reduced irritation (device/formulation)
• Titration and combination regimens that align with craving patterns (clinical evidence capture)
• Faster-onset short-acting formulations where regulation permits and where differentiation can be maintained

Because the active molecule is mature, “clinical differentiation” must translate into:

• measurable improvements in abstinence,
• adherence and persistence,
• or safety/comfort metrics that drive repeat use.

If you are evaluating market entry or expansion

Model category growth by:

• store and pharmacy access (including OTC shelf reach),
• program inclusion in cessation services,
• and regional differences in generic penetration.

Key Takeaways

• Nicotine’s clinical landscape is dominated by delivery-format evidence and combination dosing rather than new molecular entities.
• Market growth is driven by cessation attempts, adherence, and mix shift toward combination regimens, while constrained by generic pricing pressure and substitution by other cessation drugs.
• Investment-grade differentiation typically sits in device/formulation IP and regimen-driven clinical outcomes, not in the nicotine active ingredient itself.
• Projections should be built on units (quit attempts times treatment duration), mix (patch-only vs combination), and pricing by channel, then sensitivity-tested by substitution intensity.

FAQs

1) Is nicotine NRT still clinically relevant versus prescription smoking cessation drugs?

Yes. Guidelines and aggregated clinical evidence continue to support NRT as effective for smoking cessation and as a standard option within structured cessation care, often used alone or combined with behavioral support [1–4].

2) Do combination regimens outperform patch-only approaches?

Evidence syntheses and guideline recommendations support combination use in many populations, particularly to manage breakthrough cravings, which can improve abstinence outcomes relative to patch-only strategies [1–4].

3) What product differentiation can still matter economically in nicotine NRT?

Differentiation typically comes from delivery experience and compliance drivers: patch comfort and adherence, short-acting speed and dosing convenience, and formulation/device improvements that maintain efficacy with fewer irritation-related discontinuations.

4) Are patents on nicotine itself a meaningful investment factor?

No. The active ingredient nicotine is long established. Commercially relevant IP is usually tied to specific formulations, devices, or use/regimen strategies within particular jurisdictions.

5) What is the biggest determinant of market performance for nicotine NRT brands?

Channel access and adherence-linked effectiveness: how often patients can start, correctly use, and continue the regimen through the quit window.

---

References (APA)

[1] U.S. Department of Health and Human Services. (2020). Treating Tobacco Use and Dependence: 2008 Update. Public Health Service. https://www.ncbi.nlm.nih.gov/books/
[2] National Institute for Health and Care Excellence (NICE). (2023). Smoking cessation: preventing relapse in people with mental health conditions. NICE guideline (updated). https://www.nice.org.uk/
[3] U.S. Preventive Services Task Force. (2021). Tobacco smoking cessation interventions. Final Recommendation Statement. https://www.uspreventiveservicestaskforce.org/
[4] World Health Organization. (2019). WHO report on the global tobacco epidemic. WHO. https://www.who.int/